Introduction
Despite modern heart failure (HF) therapy, the prognosis of patients with HF remains poor. 1 Risk estimation in this heterogeneous patient population has shown that HF patients frequently suffer from comorbidities. These comorbidities are not only prevalent, but also pose excess mortality risk. 2, 3 As it plays a crucial role in the pathophysiology of HF, the most important comorbidity is renal impairment. 4 Defined as baseline reduction in glomerular filtration, or a worsening of renal function (WRF) over time, renal impairment has been associated with reduced survival in patients with HF over the past two decades. [5] [6] [7] In 2006, some six years after the first report on renal dysfunction and outcome in HF, a first meta-analysis showed a greatly increased mortality risk associated with renal impairment. In 2007, WRF was consistently found to increase mortality risk in HF. 8, 9 However, these meta-analyses predominantly included patients recruited many years ago. Numerous new studies have since investigated the relationship between renal dysfunction and outcome, including patient populations that more closely resemble the modern HF populations. In the present analysis, we performed an updated meta-analysis of the relationship between baseline renal impairment, worsening renal function (WRF), and outcome, as well as an analysis of the clinical predictors of WRF in HF.
Methods

Literature search
MEDLINE was searched to identify eligible studies using search tools provided by PubMed (http://www.ncbi.nlm.nih.gov/pubmed/clinical) and via OVID (from inception to 1 July 2012). We used keywords including renal function, renal failure, chronic kidney disease, CKD, glomerular filtration rate, creatinine, cystatin C, blood urea nitrogen, GFR, heart failure, cardiac failure, CHF, AHF, ADHF, and combinations thereof. Inclusion was limited to papers published in the English language. Furthermore, we searched our own files, reviewed reference lists from eligible studies, used the 'see related articles' feature in PubMed, consulted the Cochrane Library, and searched the ISI Web of Knowledge (http://scientific.thomson.com/webofknowledge) to identify key publications. Abstracts and manuscripts were reviewed independently by two authors (K.D. and M.A.E.V.). Disagreements were solved by consensus. The corresponding author was contacted as needed to obtain data not included in the published report.
Study selection
Our primary analyses encompassed the following studies: (i) studies investigating the relationship between baseline renal function and outcome in HF and (ii) studies investigating the relationship between WRF and outcome in HF. For both primary analyses, articles were excluded if: (i) no crude mortality data for the study groups were available even after contact with the authors, (ii) data were only published in abstract form, and (iii) no definition for HF was given. For the baseline renal function analysis, all studies investigating chronic kidney disease (CKD) as defined by the individual studies were included. Chronic kidney disease in the individual studies had to be defined in one of the following ways: according to K/DOQI criteria [estimated glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 ], other cut-offs for estimated GFR, creatinine, blood urea nitrogen or cystatin C or a combination thereof, or appropriate International Classification of Diseases (ICD) codes. For the WRF analysis, only studies that provided detailed description of the definition of WRF were included-either a decrease in estimated GFR, or an increase in serum creatinine or cystatin C over time. The primary outcome measure was defined as all-cause mortality at any time during hospitalization, shortly after hospitalization, or long-term outhospital mortality. Mean or median follow-up times from individual studies were used, and follow-up time for studies only reporting inhospital follow-up was set to 10 days.
Study quality
The quality of the individual studies was assessed on 11 criteria: (1) sufficiently specified inclusion and exclusion criteria; (2) sufficient explanation of sample selection; (3) specification of clinical and demographic variables; (4) representativeness of the study sample for the mentioned patient population; (5) specification of outcome measures; (6) definition of renal insufficiency/WRF; (7) assessment of a 'dose-response' relationship between the extent of renal dysfunction/WRF and outcome; (8) adjustment for possible confounders in the analysis; (9) reporting of loss to follow-up rates; (10) study design; and (11) duration of follow-up. Two independent authors assessed study quality (K.D. and M.A.E.V.). The mean of both scores was used for final grading of study quality. Grading was as follows; good quality: 8-11 criteria, fair quality: 5-7 criteria, and poor quality: <5 criteria.
Statistical analysis
Meta-analysis was performed using a random effects model to determine risk associated with the presence of either baseline CKD/WRF and all-cause mortality, as measured by combined crude mortality rates. In the secondary analysis, multivariate adjusted hazard ratios were pooled using inverse variance random effects models for either CKD or severe renal insufficiency. Severe renal insufficiency was defined as presented in the individual studies: depending on published subgroup data, lowest estimated GFR, or highest creatinine/cystatin C group/quartiles were used. Inter-study heterogeneity of risk estimates was examined using a standard χ 2 test and I 2 statistic for heterogeneity. I 2 is the percentage of variance that is due to inter-study variance. Reasons for diversity in study results were explored using random effects meta-regression analysis. Variables investigated in meta-regression were: year of publication, total number of patients, acute vs. chronic HF, gender, mean age, race, mean follow-up time, left-ventricular ejection fraction (LVEF), mean baseline blood pressure, ischaemic aetiology, history of hypertension, diabetes or atrial fibrillation, renin-angiotensin system inhibitor use, diuretic use, beta-blocker use, aldosterone receptor antagonist use, baseline GFR, prevalence of CKD, base-line creatinine, study design, and baseline haemoglobin levels, all if available. In secondary analysis, random effects meta-analysis for predictors of WRF was carried out with WRF as the outcome variable. For this analysis, baseline CKD, age, diuretic use, and a history of hypertension or diabetes were modelled separately in random effects models. A funnel plot was constructed to visually investigate possible confounding in published studies. The Metatrim command, which uses the imputation method by Duval and Tweedie 10 to account for the asymmetry of the funnel plot, was used to address significant publication bias where present. Results are presented as odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) and P-values. All reported probability values are two-tailed, and a P-value of <0.05 was considered statistically significant. Statistical analyses were performed using Stata 10.0, College Station, TX, USA and Revman 5.1.
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Results
Our initial search identified a total of 68 studies that investigated baseline CKD or WRF and prognosis in HF. After contact with individual authors, another 17 studies with crude mortality rates were identified, resulting in 57 studies investigating baseline CKD and outcome, and 28 studies investigating WRF and outcome in HF. [5] [6] [7] In total, 55 of the 82 unique studies were of good study quality, 23 studies were of fair quality, and four studies were of poor quality. 1 076 104 patients with HF were included in the individual studies used for the CKD analyses, while a total of 49 890 HF patients were included in those for the WRF analyses. Design, number of included patients and baseline characteristics per study are presented in Tables 1 and 2 . The QUOROM diagrams in Figure 1 show the inclusion and exclusion of identified studies. Notably, the MAGGIC individual patient meta-analysis was excluded in the primary analysis because of a large overlap with included studies, and introduced as a replacement for these studies in secondary analysis. Furthermore, we included the study by Testani et al. 79 from the ESCAPE trial instead of the study by Nohria et al. 91 , since the latter did not report crude mortality rates. For the WRF substudy of the SOLVD studies, we included the study by Khan et al. 88 instead of Testani et al. 92 for similar reasons. Mean age among all studies was 69 ± 7 years, 62% male. Among studies with published ejections fractions (n = 53), mean LVEF was 34 ± 8%, while LVEF was preserved (with cut-off for preserved LVEF being different across studies) in 34% (range 8-100) of patients in 27 studies. Mean estimated GFR was 62 ± 9 mL/min/1.73 m 2 , with a mean serum creatinine of 120 µmol/L (1.36 ± 0.20 mg/dL).
Baseline chronic kidney disease and all-cause mortality Of 1 076 104 patients, in total, 32% had CKD as defined in the individual studies. Excluding the registries by Kao and Herzog et al., which reported significantly lower figures, overall CKD prevalence was 49%, with higher prevalence in studies in acute HF (53%) vs. chronic HF (42%). After a mean follow-up of 681 ± 704 days (acute HF: 361 ± 333 days, chronic HF: 942 ± 802 days), the crude mortality rates for patients with and without CKD at baseline were 16 and 11%, respectively. This resulted in a combined unadjusted odds ratio (OR) for mortality of 2.34, 95% CI 2.20-2.50, P < 0.001 ( Figure 2 ). This effect was slightly greater in acute (OR = 2.39, 95% CI 2.25-2.54, P < 0.001) vs. chronic HF (OR = 2.26, 95% CI 2.08-2.47, P < 0.001). Excluding studies with only inhospital mortality data, the effect in acute HF was even more pronounced (OR = 2.50, 95% CI 2.28-2.75, P < 0.001). The effect of CKD in studies that used a cut-off of eGFR < 60 mL/min was similar (OR = 2.28, 95% CI 2.10-2.47, P < 0.001). For the overall effect, the Funnel plot showed no evidence of publication bias (Figure 3) . A total of 44 studies assessed the multivariate adjusted mortality risk associated with moderate CKD, while 22 studies assessed adjusted mortality risk associated with severe renal impairment. Moderate CKD showed consistent association with poor outcome with an adjusted HR of 1.59, 95% CI 1.49-1.69, P < 0.001, while severe renal impairment was strongly associated with poor outcome in adjusted analysis: HR 2.17, 95% CI 1.95-2.40, P < 0.001. Significant heterogeneity was present in the main study analysis (I 2 = 91%, P < 0.001), similar to the heterogeneity in the adjusted analyses. In meta-regression analysis, higher LVEF, diuretic use, and shorter follow-up duration were associated with the effect of CKD on outcome. The presence of CKD was of greater prognostic importance in patients DM, history of diabetes; HFPEF, heart failure with preserved ejection fraction; HT, history of hypertension; IHD, ischaemic heart disease; F/U, follow-up; LVEF, left-ventricular ejection fraction; sCr, serum creatinine.
Table 2
Characteristics of studies included in the WRF analysis with more preserved LVEF, more frequent diuretic use, and with shorter follow-up. Figure 4 shows the different effect estimates of the presence of CKD, dependent on mean LVEF in the individual studies. Study quality was not associated with changes in the effect estimate. In a sensitivity analysis, excluding the study by Kao et al. 37 which was exceptionally large but of poor quality, the results were consistent: OR 2.34, 95% CI 2.20-2.50, P < 0.001. The results remained consistent in a second sensitivity analysis, excluding another four studies (NHCP, ANCHOR, ADHERE, and the study by Herzog), comprising 79% of the remaining study population: OR 2.37, 95% CI 2.21-2.54, P < 0.001. 14, 46, 48, 93 Finally, including data from the MAGGIC individual patient data meta-analysis, and excluding studies examined in this meta-analysis to prevent duplicate cases, 5,32,42,50, the results remained consistent: OR 2.35, 95% CI 2.20-2.50, P < 0.001.
Worsening renal function and all-cause mortality Of 49 890 patients, a total of 11 476 (23%) had WRF as defined in the individual studies. The definitions used for WRF are shown in Table 2 . Prevalence of WRF was slightly lower in studies in acute HF (23%) vs. chronic HF (25%). After a mean follow-up of 448 ± 569 (range 10-2555) days (acute HF: 418 ± 594 days, chronic HF: 584 ± 476 days), the crude mortality rates for patients with and without WRF were 36 and 32%, respectively. This resulted in a combined unadjusted OR for mortality of 1.81, 95% CI 1.55-2.12, P < 0.001 ( Figure 5 ). This effect was less pronounced in acute (OR = 1.75, 95% CI 1.47-2.08, P < 0.001) vs. chronic HF (OR = 1.96, 95% CI 1.48-2.61, P < 0.001). Excluding studies that assessed only inhospital mortality, the total effect of WRF was less pronounced (OR = 1.67, 95% CI 1.43-1.95, P < 0.001). The effect of WRF in studies that investigated the most generally used definition of >26.5 µmol/L (0.3 mg/dL) increase in serum creatinine was slightly lower compared to the overall effect (OR = 1.54, 95% CI 1.29-1.85, P < 0.001).
The Funnel plot is asymmetric for the overall effect ( Figure 6 ). Larger effects are observed with greater standard errors, which suggests the possibility of publication bias. Metatrim indicated that 12 studies with positive/neutral effects of WRF were missing. Adding these studies into the random pooled analysis resulted in a significant effect of WRF on outcome: OR 1.34, 95% CI 1.14-1.56, P < 0.001. Significant heterogeneity was also present (I 2 = 83%, P < 0.001). In meta-regression analysis, only study size and haemoglobin levels showed a trend towards affecting the relationship between WRF and outcome. The risk associated with the presence of WRF was smaller in larger studies and studies with lower haemoglobin levels. Study quality was not associated with changes in the effect estimate. In a sensitivity analysis, excluding Kociol et al. 74 which comprises 40% of the study population, the results remained consistent: OR 1.84, 95% CI 1.59-2.14, P < 0.001. In 10 studies assessing the multivariate adjusted association between the occurrence of WRF and mortality, WRF was associated with a significantly increased mortality risk: HR 1.95, 95% CI 1.45-2.62, P < 0.001. A total of 29 studies investigated the predictors of WRF in patients with HF. 12, 13, 35, 60, 66, [68] [69] [70] [71] [73] [74] [75] [76] [77] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [94] [95] [96] [97] [98] [99] Table 3 shows the predictors of WRF in the individual studies. In almost every study, lower baseline estimated GFR/higher creatinine was a significant predictor of the occurrence of WRF, while other prominent predictors were age, diabetes, hypertension, anaemia, and the use of diuretics. Pooling independent risk estimates of predictors of WRF in different studies identified baseline CKD, a history of hypertension and diabetes, age, and diuretic use as significant predictors of the occurrence of WRF in meta-analysis ( Table 4) .
Discussion
Baseline renal impairment and WRF are common in patients with acute and chronic HF. When present, both entities are associated with strongly reduced survival rates, although the presence of CKD shows more consistent effects on mortality. Worsening renal function during or following hospitalization showed a strong relationship with long-term outcome. Across included studies, important patient characteristics were identified that may predict the occurrence of WRF.
Baseline chronic kidney disease and mortality in heart failure Although the importance and pathophysiologic involvement of renal failure in HF Figure 4 Forest plot of combined all-cause mortality for CKD vs. no CKD, stratified by mean LVEF of included studies. CKD, chronic kidney disease; LVEF, left-ventricular ejection fraction.
31 Figure 5 Forest plot of combined all-cause mortality for WRF vs. no WRF, stratified by acute and chronic heart failure. WRF, worsening renal function. has been recognized for over a century, the prognostic significance of a reduction in GFR has only been studied for little over a decade. In the first studies, retrospective analyses of the SOLVD studies and PRIME II study, impaired renal function was associated with strongly reduced survival rates, independently of left-ventricular function and severity of HF. 6, 7 In subsequent years, 15 studies on renal impairment and outcome in HF were published, resulting in the meta-analysis by Smith et al. in 2006. 9 Over 80 000 HF patients were included in this meta analysis, which found that any degree of renal impairment was associated with a 56% increase in relative mortality risk. Our current meta-analysis further extends this observation. Importantly, our analysis included over 10 times the number of patients with HF, and found a strikingly similar association between any degree/moderate CKD and prognosis. Some important differences should be acknowledged, however. Our present study also included HF patients with a preserved ejection fraction (HFPEF). Although a minority across included studies, the mortality risk associated with CKD showed dependency on LVEF, suggesting CKD may be an even more powerful predictor of outcome in patients with HFPEF. This observation contrasts with findings from the MAGGIC individual patient data meta-analysis, which recently found reduced eGFR to be a stronger predictor of outcome in patients with reduced versus preserved LVEF. 100 It must be acknowledged, however, that our current meta-analysis included limited number of patients with a truly preserved ejection fraction, whichalong with the differences in analytical approach, included studies and continuous Figure 6 Funnel plot of the main worsening renal function analysis. 66 Forman 68 De Silva 86 Khan 88 Owan 69 Logeart 94 Cowie 70 Jose 87 Akhter 12 Metra 73 Weinfeld 95 Chittineni 71 Damman 60 Aronson 13 Belziti 76 Breidthardt 83 Herout 77 Kociol 74 Lassus 75 Voors 96 Voors 84 Blair 35 Lanfear 85 Rusinaru 82 Testani 97 Testani 79 Testani 80 Verdiani 81 Rossignol 98 Maeder 99 Baseline GFR X X X X X X X X X X X X X X X X X X X X X X X X X X X X versus dichotomous classification of estimated GFR-may partly explain these. Possible explanations for the observation that CKD is related to a higher mortality risk in HFPEF include underlying disease, such as hypertension and diabetes, both of which are associated with impaired eGFR and worse outcome. In general, patients with a relatively preserved ejection fraction present with a different clinical and biochemical profile, and possibly a different reason for a lower eGFR, all of which could explain the observed effect. Future research, especially in HFPEF, is needed to examine these relationships.
Other important differences compared with the meta-analysis by Smith et al. include the number of studies investigated, 35 of which were published after the meta-analysis by Smith et al., and the unlimited follow-up duration in our analysis. The results of these two meta-analyses and another meta-analysis by Tonelli et al. 101 represent robust evidence for the association between CKD and mortality in HF. This effect seems to be present irrespective of the setting; in both acute and chronic HF, baseline renal impairment was associated with poor outcome, with a greater effect in the acute setting. Baseline CKD in each setting may represent different pathophysiologic mechanisms, as CKD in the chronic setting may be the result of steadily decreasing GFR, while the increasingly congestive state in the acute setting may lead to a more pronounced decrease in GFR in a much shorter timespan. It is clear that any degree of renal impairment should be considered a strong and important risk stratifier in patients with HF.
Worsening renal function and mortality in heart failure Of even greater importance for treatment guidance, and possibly as a marker for treatment effect, dynamics changes in renal function are frequently observed in patients with HF. In a previous meta-analysis in over 18 000 patients with HF, we found that about 25% developed some degree of WRF during follow-up. 8 In our present study, which extended the analyses to over 45 000 patients, we found a similar prevalence of WRF, independently of the setting of HF. In agreement with 35 findings in CKD, the mortality risk observed for WRF in our current meta-analysis was at least as large as in our previous analysis. This association persisted after adjustment for confounders in the individual studies, although further correction for publication bias slightly weakened the association. While it is important to realize that patients with WRF are at increased risk for impaired outcome, it may be far more interesting to identify patients at risk for WRF in the first place. We found that individual studies assessing this clinically relevant question consistently identified baseline renal impairment as the most important risk factor for the development of WRF, even after adjustment for confounders. In part, this implies baseline renal failure leads to impaired survival via WRF, and that WRF is a reflection of reduced GFR. Another reason for this relationship lies in the definition of WRF. In most studies, WRF is defined as an absolute increase in serum creatinine. This indirectly implies that similar absolute changes in serum creatinine represent a smaller decline in GFR for patients with lower baseline GFR compared with patients with higher baseline GFR. It also means that the effect of this smaller decrease translated into a similar mortality risk suggesting that patients with lower baseline eGFR may be more susceptible to a WRF-induced mortality risk. However, the observed effect of WRF on mortality was not dependent on baseline GFR. Interestingly, we found that when WRF was defined as a reduction in eGFR, as was the case in two studies, higher baseline GFR was associated with more frequent WRF. 88, 98 This is probably a reflection of an improper or different definition of WRF and statistical confounding, which is supported by the finding in 26 other studies that impaired baseline GFR is associated with WRF. Other important predictors of WRF include age and the presence of diabetes, hypertension, and anaemia-entities also linked to CKD and progression of CKD in various patient populations. Diuretic use and higher diuretic doses were also associated with a higher incidence of WRF, although the precise pathophysiology underlying this link is unclear. On the one hand, diuretics should reduce congestion, thereby improving renal perfusion and intrarenal pressures in some patients; on the other hand, diuretics may have direct detrimental effects on glomerular filtration. 4, 102 Multiple studies suggest the underlying reason for the occurrence of WRF may be an important mediator of the effect of WRF on outcome. In acute HF, a degree of transient WRF would appear to be tolerable, as this was not associated with poor outcome in the DOSE trial. 103 On the other hand, when WRF is associated with decreases in systolic blood pressure in acute HF, it is strongly related to poor outcome. 79, 84, 98, 104 However, WRF or change in serum creatinine were not associated with changes in haemodynamic parameters in the ESCAPE study. 91 The clinical situation in which WRF develops may be important, as at least one study showed that WRF in the context of persistent signs and symptoms of congestion was related to poor outcome, while WRF in the presence of favourable changes in clinical signs was not. 105 In chronic HF, WRF occurring without intervention is strongly related to poor outcome, while WRF ocurring in the setting of uptitration of angiotensin-converting enzyme inhibitors is not. 88, 92 Finally, various studies have shown relationships between persistent WRF, transient WRF, or even any change (increase or decrease) in serum creatinine and poor outcome. 13, 79, 94 These findings suggest that clinical setting, the cause of WRF (during treatment, initiation of therapy, longterm follow-up), and associated haemodynamic changes are of major importance for evaluating the significance of WRF, further emphasizing the heterogeneity of the HF population and its response to WRF.
Finally, our meta-analysis highlights that increases in serum creatinine and related changes in GFR are associated with increased mortality. However, this does not directly imply that survival improves if serum creatinine decreases. Only in one study in chronic HF was improvement in serum creatinine associated with improved survival. 86 Most importantly, no study to date has evaluated whether therapy targeting improvement or preservation of renal function leads to improved survival. Although the PROTECT trial aimed to improve renal function using Rolofylline therapy, the investigational drug actually significantly increased serum creatinine levels, suggesting that either the treatment failed to improve renal function, or that serum creatinine is a poor marker for renal function in the acute stages of treatment. 96 To provide an answer to this important clinical question, studies are needed that identify individual patients at risk for WRF, adequately define or calculate (changes in) renal function, and are focused on preservation or improvement of renal function over time.
Limitations
We found possible evidence of publication bias in the analysis on WRF and outcome. This suggests that studies reporting higher mortality risk with WRF are published more often, which meaning the observed increased mortality risk with WRF in our analysis may be an overestimation of true risk. This is further strengthened by our observation that mortality risk associated with WRF was higher in smaller studies. Furthermore, although we tried to gather all information available, we could not acquire crude data for all studies, which included at least one study that showed a limited effect of WRF on mortality, and two important clinical trials in acute HF. 96, 99, 103 Other inherent limitations of meta-analysis include significant heterogeneity among studies, which was the reason for using a random effect model. However, this will never fully account for intrinsic differences between included studies. Importantly, we found significant heterogeneity in all analyses, suggesting that the observed risk associated with both WRF and CKD may not be applicable to all patient populations in HF. Reasons for diversity among studies include the differing inclusion criteria, selection bias, different cut-off for both WRF and CKD, and the shift in the type of HF patients from reduced to more preserved ejection fraction seen in recent years. The patient cohorts included were also relatively younger than observed in a general HF population, which may lead to some underestimation of the prevalence of both CKD and WRF. We have tried to account for some degree of heterogeneity via meta-regression, but as not all studies published important covariates, meta-regression could only be performed using a limited number of studies and variables. Furthermore, we used mean values for variables reported by included studies, which does not account for in-study variance. Individual pa-37 tient-level data would be needed to confirm our results. Importantly, we could not establish whether there are specific patients or patient groups that have a different response to renal impairment or WRF. These observations highlight limitations to the generalizability of our findings. Finally, we did not include a meta-analysis of continuous data, as studies reporting such data were limited and used divergent cut-off points. Use of continuous data could potentially have shown better accuracy.
Conclusions
Baseline renal impairment and WRF over time are frequently observed in patients with acute and chronic HF. When present, both entities relate to strongly impaired survival, with the presence of CKD showing a more consistent relationship with poor outcome. Across studies, baseline CKD, a history of hypertension and diabetes, age, and diuretic use are associated with the occurrence of WRF.
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